NU52PS910266
Cooperative Agreement
Overview
Grant Description
Tuberculosis elimination and laboratory cooperative agreement - the New Jersey Department of Health (NJDOH) Tuberculosis (TB) program conducts statewide surveillance by housing and maintaining the state TB disease registry.
Additionally, the program provides financial assistance, direct assistance, material support, technical assistance, and education to strengthen TB prevention and control activities at local health departments throughout the state.
The NJDOH TB program ensures continuity of care by tracking TB case-patients migrating in to and out of New Jersey and the United States.
The program also provides health service grant funding to partially fund eight regional TB clinics.
Local TB programs are funded through a combination of sources unique to each site: levies, general revenue funds, private hospitals, and endowments from corporate or community groups.
Where needed, the NJDOH TB program provides on-site expert guidance for the investigation of TB cases, clusters and outbreaks, and conducts regional trainings to address specific needs.
Expert TB medical consultation for complex cases is provided by the Global TB Institute and the TB Medical Advisory Board.
The Global TB Institute in Newark has been designated a TB Center of Excellence by the CDC and serves as a federally funded regional training and medical consultation consortia, providing trainings and webinars for public health nurses and TB clinicians throughout New Jersey and the northeastern United States.
New Jersey is the fourth smallest and most densely populated state, with more than 1,200 people per square mile.
In 2023, the population was 9.2 million; 51.0 percent females and 49.0 percent males.
Regarding race/ethnicity, the largest segment of the population is White (52.0%) followed by Hispanic (22.7%), Black (15.5%), and Asian (10.6%).
In 2023, foreign-born persons accounted for 23.2 percent of the population or approximately 2.1 million people.
There has been a 65.1 percent decrease in tuberculosis (TB) morbidity in New Jersey since 1992 (the peak of TB resurgence in the US).
Following two decades of steadily decreasing incidence, the rate of decline began to slow, or level off, between 2012—2019.
However, since 2020, TB case counts and rates have increased each year, culminating in 343 cases in 2023, with a corresponding incidence rate of 3.7 cases per 100,000 population.
Although the incidence of TB has been generally declining since 1992, both in the US and New Jersey, the incidence rate of TB in New Jersey remains higher than the national rate of 2.9, and the 343 cases counted in 2023 represents the largest number of newly diagnosed cases of TB in New Jersey since 2010 (N= 405).
Aside from the recent increases in incidence and prevalence, TB remains a disease of major public health importance in New Jersey due to its airborne mode of transmission and the emergence of drug resistant strains of the bacterium.
Additionally, the program provides financial assistance, direct assistance, material support, technical assistance, and education to strengthen TB prevention and control activities at local health departments throughout the state.
The NJDOH TB program ensures continuity of care by tracking TB case-patients migrating in to and out of New Jersey and the United States.
The program also provides health service grant funding to partially fund eight regional TB clinics.
Local TB programs are funded through a combination of sources unique to each site: levies, general revenue funds, private hospitals, and endowments from corporate or community groups.
Where needed, the NJDOH TB program provides on-site expert guidance for the investigation of TB cases, clusters and outbreaks, and conducts regional trainings to address specific needs.
Expert TB medical consultation for complex cases is provided by the Global TB Institute and the TB Medical Advisory Board.
The Global TB Institute in Newark has been designated a TB Center of Excellence by the CDC and serves as a federally funded regional training and medical consultation consortia, providing trainings and webinars for public health nurses and TB clinicians throughout New Jersey and the northeastern United States.
New Jersey is the fourth smallest and most densely populated state, with more than 1,200 people per square mile.
In 2023, the population was 9.2 million; 51.0 percent females and 49.0 percent males.
Regarding race/ethnicity, the largest segment of the population is White (52.0%) followed by Hispanic (22.7%), Black (15.5%), and Asian (10.6%).
In 2023, foreign-born persons accounted for 23.2 percent of the population or approximately 2.1 million people.
There has been a 65.1 percent decrease in tuberculosis (TB) morbidity in New Jersey since 1992 (the peak of TB resurgence in the US).
Following two decades of steadily decreasing incidence, the rate of decline began to slow, or level off, between 2012—2019.
However, since 2020, TB case counts and rates have increased each year, culminating in 343 cases in 2023, with a corresponding incidence rate of 3.7 cases per 100,000 population.
Although the incidence of TB has been generally declining since 1992, both in the US and New Jersey, the incidence rate of TB in New Jersey remains higher than the national rate of 2.9, and the 343 cases counted in 2023 represents the largest number of newly diagnosed cases of TB in New Jersey since 2010 (N= 405).
Aside from the recent increases in incidence and prevalence, TB remains a disease of major public health importance in New Jersey due to its airborne mode of transmission and the emergence of drug resistant strains of the bacterium.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Funding Agency
Place of Performance
New Jersey
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 1643% from $294,079 to $5,125,175.
New Jersey Department Of Health was awarded
New Jersey TB Program : Enhancing Surveillance Control Efforts
Cooperative Agreement NU52PS910266
worth $5,125,175
from National Center for HIV, Viral Hepatitis, STD, and TB Prevention in January 2025 with work to be completed primarily in New Jersey United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.940 HIV Prevention Activities Health Department Based.
The Cooperative Agreement was awarded through grant opportunity Tuberculosis Elimination and Laboratory Cooperative Agreement.
Status
(Ongoing)
Last Modified 8/5/26
Period of Performance
1/1/25
Start Date
12/31/29
End Date
Funding Split
$5.1M
Federal Obligation
$0.0
Non-Federal Obligation
$5.1M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for NU52PS910266
Transaction History
Modifications to NU52PS910266
Additional Detail
Award ID FAIN
NU52PS910266
SAI Number
NU52PS910266-2980354543
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
State Government
Awarding Office
75CDC1 CDC Office of Financial Resources
Funding Office
75CVJ0 CDC NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TUBERCULOSIS PREVENTION
Awardee UEI
MQKPEU6D1BT5
Awardee CAGE
3MWJ7
Performance District
NJ-90
Senators
Robert Menendez
Cory Booker
Cory Booker
Modified: 8/5/26